Medline ® Abstracts for References 2,21
of 'Causes of rhabdomyolysis'
2
TI
Rhabdomyolysis: a review of the literature.
AU
Khan FY
SO
Neth J Med. 2009;67(9):272.
Rhabdomyolysis is a potentially life-threatening syndrome that can develop from a variety of causes; the classic findings of muscular aches, weakness and tea-coloured urine are non-specific and may not always be present. The diagnosis therefore rests upon the presence of a high level of suspicion of any abnormal laboratory values in the mind of the treating physician. An elevated plasma creatine kinase (CK) level is the most sensitive laboratory finding pertaining to muscle injury; whereas hyperkalaemia, acute renal failure and compartment syndrome represent the major life-threatening complications. The management of the condition includes prompt and aggressive fluid resuscitation, elimination of the causative agents and treatment and prevention of any complications that may ensue. The objective of this review is to describe the aetiological spectrum and pathophysiology of rhabdomyolysis, the clinical and biological consequences of this syndrome and to provide an appraisal of the current data available in order to facilitate the prevention, early diagnosis and prompt management of this condition.
AD
Department of Medicine, Hamad General Hospital, Doha, Qatar. fakhanqal@yahoo.co.uk
PMID
21
TI
Rhabdomyolysis following electrical injury.
AU
Brumback RA, Feeback DL, Leech RW
SO
Semin Neurol. 1995;15(4):329.
Severe electrical injury is often associated with acute rhabdomyolysis, evident from massively elevated serum creatine (CK) levels, along with presence of other muscle fiber constituents in the serum and urine, resulting specifically in hyperkalemia, hyperphosphatemia, and myoglobinuria. The acute medical care of the patient with electrical injury must include addressing supportive therapy for the rhabdomyolysis (more fully reviewed in other articles in this issue of Seminars), but understanding the underlying pathophysiology of rhabdomyolysis may allow for the future development of improved therapeutic modalities.
AD
Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA.
PMID
